Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Tulln An Der Donau – page 61

881 clinical trials in Tulln An Der Donau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tulln An Der Donau at a glance
881
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

881 trials in Tulln An Der Donau

Open in trial search

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study on the Effectiveness and Safety of Vonicog Alfa with or without Octocog Alfa for Children with Severe von Willebrand Disease Experiencing Bleeding or Undergoing Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Octocog Alfa
  • Sponsor:Baxalta Innovations GmbH

Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Renal transplant

Not recruiting

Study on the Safety and Effectiveness of Regtivex and Tocilizumab in Patients Receiving HLA-Mismatched Living Donor Kidney Transplants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Regtivex
  • Sponsor:Medical University Of Vienna

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel
  • Sponsor:Celgene Corp.

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Tulln An Der Donau

What the registry says about research in the country

01 Neurological Disorders

Research focusing on Multiple System Atrophy and its associated conditions, particularly investigating new therapeutic approaches for managing neurogenic orthostatic hypotension. Studies aim to evaluate novel treatments for improving patient symptoms and quality of life.

  • Orthostatic Hypotension Management
  • Autonomic Nervous System Disorders
  • Symptomatic Treatment Evaluation

Current trials are examining long-term effectiveness and durability of new therapeutic interventions.

02 Neuropathic Pain Studies

Comprehensive research into various forms of chronic neuropathic pain, including diabetic polyneuropathy and post-operative peripheral neuropathy. Studies are evaluating new therapeutic options for patients with treatment-resistant conditions.

  • Diabetic Polyneuropathy
  • Traumatic Neuropathy
  • Central Neuropathy

Investigations focus on add-on treatments to enhance current pain management protocols.

03 Chronic Pain Management

Innovative research targeting chronic back pain and various pain conditions, evaluating new therapeutic approaches for improved patient outcomes. Studies are designed to assess both efficacy and tolerability of novel treatment options.

  • Back Pain Treatment
  • Pain Management Protocols
  • Treatment Tolerability Assessment

Current research emphasizes developing comprehensive pain management solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.